3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
2
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Esophageal Neoplasms
1
Desmoid Tumors
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
18
Nivolumab
13
avelumab
10
Ipilimumab
7
Specimen Handling
6
cemiplimab
5
atezolizumab
5
Magnetic Resonance Spectroscopy
5
Biopsy
5
Radiotherapy
3
Cyclophosphamide
3
prednylidene
2
poly ICLC
2
lutetium Lu 177 dotatate
2
fludarabine phosphate
2
fludarabine
2
durvalumab
2
deltacortene
2
aldesleukin
2
Radiosurgery
2
Prednisone
2
Interleukin-2
2
Immunoglobulin G
2
Docetaxel
2
CTLA-4 Antigen
2
Bevacizumab
2
tocilizumab
1
talimogene laherparepvec
1
sargramostim
1
relatlimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Merkel Cell
×
High-Intensity Focused Ultrasound Ablation
×
1 year
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled